Security Snapshot

ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) Institutional Ownership

CUSIP: 682310875

13F Institutional Holders and Ownership History from Q2 2018 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

1

Shares (Excl. Options)

13.29KFull value: 13,290 · shares · 30 Jun 2026

Price

$0.95

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock, no par value
Symbol
ONCY on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
13,290
Latest holder snapshot 5 signals
Total 13F value
$12,624
Portfolio coverage rank
0%
Share change
-2,581,856
Value change
-$2,252,418
Number of holders
1
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
109,272,143
SEC-reported price per share
$0.85
Insider filing price
$0.85
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • ONCY - ONCOLYTICS BIOTECH INC - Common Stock, no par value is tracked under CUSIP 682310875.
  • 1 institution reported positions in Q2 2026.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 57 to 1 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $2.61MFull value: $2,605,687 · USD · 31 Mar 2026
    to
    $12.62KFull value: $12,624 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 1 institution filings for Q2 2026.

Open SEC evidence

Security key

682310875

13F reference period

Q2 2026

13F holders

1

13D/G owners

1

CIK / CUSIP context first

Open Q2 2026 holders ONCY full holder history ONCOLYTICS BIOTECH INC SEC filings ONCOLYTICS BIOTECH INC company facts ONCOLYTICS BIOTECH INC insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
1
Security
ONCY
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Anson Funds Management LP 7% -26% $10,708,670 -$751,370 7,649,050 -6.6% Anson Funds Management LP 30 Sep 2025
As of 30 Jun 2026, 1 institutional investors reported holding
13.29KFull value: 13,290 · shares · 30 Jun 2026
shares of ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY). This represents 0.01% of the company’s total
109.27MFull value: 109,272,143 · shares · Stored outstanding share count
outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
34
Headline period
Q2 2026
Rows shown
1-25 of 34
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 0 $0 -$12,624 $0.85 0
2026 Q2 13,290 $12,624 -$2,252,418 $0.95 1
2026 Q1 2,996,471 $2,605,687 +$189,006 $0.85 57
2025 Q4 2,797,506 $2,449,574 -$295,679 $0.87 61
2025 Q3 2,820,198 $3,771,684 +$1,889,818 $1.40 56
2025 Q2 1,495,731 $1,150,336 +$116,133 $0.77 54
2025 Q1 1,364,360 $748,757 -$5,861 $0.55 50
2024 Q4 1,314,892 $1,206,107 +$64,784 $0.91 46
2024 Q3 999,534 $872,336 -$113,469 $0.87 40
2024 Q2 1,309,286 $1,297,302 -$118,709 $0.99 41
2024 Q1 1,409,004 $1,495,371 -$5,110,399 $1.06 35
2023 Q4 5,144,044 $6,944,143 -$1,456,985 $1.35 42
2023 Q3 6,216,229 $13,562,379 +$11,870,396 $2.18 32
2023 Q2 800,773 $2,085,599 -$679,945 $2.60 28
2023 Q1 1,103,514 $1,325,529 +$296,418 $1.20 30
2022 Q4 902,111 $1,482,300 +$321,702 $1.63 33
2022 Q3 714,327 $883,809 -$184,426 $1.23 28
2022 Q2 909,878 $911,763 +$188,561 $1.00 33
2022 Q1 697,567 $1,099,375 -$760,113 $1.58 29
2021 Q4 1,187,087 $1,652,710 +$287,570 $1.40 34
2021 Q3 903,524 $1,890,946 -$125,314 $2.09 32
2021 Q2 887,682 $2,434,336 -$773,341 $2.77 35
2021 Q1 1,038,987 $3,786,537 +$314,929 $3.81 36
2020 Q4 1,085,633 $2,586,529 +$776,286 $2.38 30
2020 Q3 776,299 $1,313,572 -$60,476 $1.69 27
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .